Posted inCardiology Hematology-Oncology news
Abelacimab Shows Superior Safety Over Rivaroxaban for Older Adults with Atrial Fibrillation
A phase 2b study demonstrates that the Factor XI inhibitor abelacimab significantly reduces bleeding risk compared to rivaroxaban in older atrial fibrillation patients, offering a safer alternative for stroke prevention in high-risk populations.




